Literature DB >> 2955044

Suppression of polyclonal antibody production in Trypanosoma cruzi-infected mice by treatment with anti-L3T4 antibodies.

P Minoprio, H Eisen, M Joskowicz, P Pereira, A Coutinho.   

Abstract

Acute Trypanosoma cruzi infection of mice results in a very marked polyclonal activation of B and T lymphocytes, accompanied by high numbers of Ig-secreting PFC and lectin-dependent effector CTL. Treatment of mice with monoclonal anti-L3T4 antibodies from the time of infection (days 0, 4, and 8) completely suppresses the polyclonal PFC response and CTL generation. Treatment of nude mice with antibody does not alter the lipopolysaccharide-induced polyclonal PFC response, and it only modulates the isotypic profile of the PFC response to T. cruzi infection, without reducing its magnitude. Furthermore, antibody-treated, T. cruzi-infected euthymic mice do not develop the typical B cell blastogenic response, but show high numbers of activated Lyt-2+ lymphoblasts in the spleen. These results indicate that effector cell generation in T. cruzi-infected mice is predominantly helper T cell-dependent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2955044

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Chagas' disease and the autoimmunity hypothesis.

Authors:  F Kierszenbaum
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

2.  Modulation of thymocyte subsets during acute and chronic phases of experimental Trypanosoma cruzi infection.

Authors:  M C Leite-de-Moraes; M Hontebeyrie-Joskowicz; M Dardenne; W Savino
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

3.  Chronic experimental Chagas' disease: functional syngeneic T-B-cell cooperation in vitro in the absence of an exogenous stimulus.

Authors:  C Freire-de-Lima; L M Peçanha; G A Dos Reis
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

4.  Trypanosoma cruzi infection induces a massive extrafollicular and follicular splenic B-cell response which is a high source of non-parasite-specific antibodies.

Authors:  Daniela A Bermejo; María C Amezcua Vesely; Mahmood Khan; Eva V Acosta Rodríguez; Carolina L Montes; Maria C Merino; Kai Michael Toellner; Elodie Mohr; Dale Taylor; Adam F Cunningham; Adriana Gruppi
Journal:  Immunology       Date:  2010-09-28       Impact factor: 7.397

5.  Altered expression of galectin-3 induces cortical thymocyte depletion and premature exit of immature thymocytes during Trypanosoma cruzi infection.

Authors:  Elizangela Silva-Monteiro; Luciana Reis Lorenzato; Oscar Kenji Nihei; Mara Junqueira; Gabriel Adrián Rabinovich; Daniel Kaiyuan Hsu; Fu-Tong Liu; Wilson Savino; Roger Chammas; Déa Maria Serra Villa-Verde
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

6.  Trypanosoma cruzi mitochondrial malate dehydrogenase triggers polyclonal B-cell activation.

Authors:  C L Montes; E I Zuñiga; J Vazquez; C Arce; A Gruppi
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

7.  Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease.

Authors:  R L Tarleton; J Sun; L Zhang; M Postan
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  BAFF mediates splenic B cell response and antibody production in experimental Chagas disease.

Authors:  Daniela A Bermejo; María C Amezcua-Vesely; Carolina L Montes; María C Merino; Ricardo C Gehrau; Hugo Cejas; Eva V Acosta-Rodríguez; Adriana Gruppi
Journal:  PLoS Negl Trop Dis       Date:  2010-05-04

9.  Specific humoral immunity versus polyclonal B cell activation in Trypanosoma cruzi infection of susceptible and resistant mice.

Authors:  Marianne A Bryan; Siobhan E Guyach; Karen A Norris
Journal:  PLoS Negl Trop Dis       Date:  2010-07-06

Review 10.  Chagas heart disease pathogenesis: one mechanism or many?

Authors:  Kevin M Bonney; David M Engman
Journal:  Curr Mol Med       Date:  2008-09       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.